Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
17 Juillet 2023 - 2:45PM
Business Wire
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a
clinical-stage biopharmaceutical company developing a broad
pipeline of novel immunotherapies by applying its proprietary
technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor
Activated Immunomodulator (TRACIr) platforms, today announced the
pricing of an underwritten offering of 4,153,717 shares of its
common stock and pre-funded warrants to purchase 583,483 shares of
common stock. The shares of common stock are being sold at a price
of $12.46 per share and the pre-funded warrants are being sold at a
price of $12.459 per pre-funded warrant, which represents the per
share price for the common stock less the $0.001 per share exercise
price for each such pre-funded warrant. The gross proceeds from the
offering to Janux are expected to be approximately $60 million,
before deducting underwriting discounts and commissions and
offering expenses. The offering is expected to close on or about
July 19, 2023, subject to the satisfaction of customary closing
conditions.
BofA Securities, Inc. is acting as sole book-runner for the
offering.
The shares are being offered by the company pursuant to a
Registration Statement on Form S-3 previously filed and declared
effective by the SEC. A final prospectus supplement and the
accompanying prospectus relating to the offering will also be filed
with the SEC. These documents can be accessed for free through the
SEC’s website at www.sec.gov.
When available, a copy of the final prospectus supplement and
the accompanying prospectus relating to the offering may also be
obtained from: BofA Securities, Inc., Attention: Prospectus
Department, NC1-004-03-43, 200 North College Street, 3rd Floor,
Charlotte, North Carolina 28255, via telephone at (800) 294-1322 or
via email at dg.prospectus_requests@bofa.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation, or sale would be unlawful before registration
or qualification under the securities laws of such state or
jurisdiction.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the ability to close the offering,
expected gross proceeds and timing for the closing of the offering.
Factors that may cause actual results to differ materially include
general economic and market conditions; and satisfaction of
customary closing conditions related to the offering. You are urged
to consider statements that include the words “may,” “will,”
“would,” “could,” “should,” “believes,” “estimates,” “projects,”
“promise,” “potential,” “expects,” “plans,” “anticipates,”
“intends,” “continues,” “designed,” “goal,” or the negative of
those words or other comparable words to be uncertain and
forward-looking. For a further list and description of the risks
and uncertainties Janux faces, please refer to Janux’s periodic and
other filings with the Securities and Exchange Commission, which
are available at www.sec.gov. Such forward-looking statements are
current only as of the date they are made, and Janux assumes no
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717647990/en/
Investors: Andy Meyer Janux Therapeutics
ameyer@januxrx.com (202) 215-2579
Media: Jessica Yingling, Ph.D. Little Dog Communications
Inc. jessica@litldog.com (858) 344-8091
Janux Therapeutics (NASDAQ:JANX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Janux Therapeutics (NASDAQ:JANX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024